NASDAQ$KROS
Keros Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Keros Therapeutics reported a net loss due to increased research and development efforts and additional infrastructure expenses.
Keros Therapeutics reported a net loss of $15.6 million for the second quarter of 2021, driven by increased research and development expenses and additional infrastructure costs. The company's cash and cash equivalents were $237.1 million as of June 30, 2021, expected to fund operations into the fourth quarter of 2023.
- Announced preliminary results from Phase 2 clinical trial of KER-050.
- Executive leadership changes with Simon Cooper appointed as Chief Medical Officer.
- Issued a foundational U.S. patent for novel therapeutic proteins, including KER-050.
- Initiated dosing for Cohort 3 of the Phase 2 clinical trial evaluating KER-050 in patients with myelodysplastic syndromes.
Headline financials
Revenue & EPS history
Keros · Revenue · Quarterly
$100K
Forward guidance
Keros expects that the cash and cash equivalents it had on hand at June 30, 2021 will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+0.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+5.0%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+34.0%
Q3 2021
Best reaction
-15.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | -17.4% | -15.4% | |
| Q4 2025 | -15.0% | -15.9% | -12.9% | |
| Q3 2025 | +3.4% | +8.0% | +38.6% | |
| Q1 2025 | +0.7% | +0.1% | -3.3% | |
| Q4 2024 | +0.6% | +5.9% | -1.4% | |
| Q3 2024 | +7.3% | +8.9% | +11.9% | |
| Q2 2024 | -8.9% | -8.0% | +7.7% | |
| Q1 2024 | -1.8% | -8.0% | -17.0% | |
| Q4 2023 | -3.6% | -1.4% | -5.4% | |
| Q3 2023 | -0.3% | -7.4% | +4.8% | |
| Q2 2023 | -10.3% | -12.9% | -12.9% | |
| Q1 2023 | -2.6% | -2.3% | +8.6% | |
| Q4 2022 | -6.4% | -3.6% | -23.4% | |
| Q3 2022 | -2.0% | -9.2% | +3.2% | |
| Q2 2022 | +14.7% | +13.5% | +10.6% | |
| Q1 2022 | -12.5% | -15.5% | -36.5% | |
| Q4 2021 | +8.7% | -3.5% | +29.9% | |
| Q3 2021 | +34.0% | +43.0% | +30.3% | |
| Q2 2021 | +5.5% | +2.6% | -3.7% | |
| Q1 2021 | -2.4% | -6.9% | -13.5% | |
| Q4 2020 | +4.4% | +6.6% | +14.0% | |
| Q3 2020 | -0.9% | +8.1% | +41.4% | |
| Q2 2020 | +7.1% | +12.8% | +23.6% | |
| Q1 2020 | -2.0% | +4.0% | +41.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro